Skip to main content

Specimen Retrieval Bag Market Top-Players And Qualitative Future Analysis Forecast Until 2028

 




Specimen retrieval bag are widely used in laparoscopic surgeries for removing adnexal cysts and masses from patients’ body. These systems are developed to reduce contamination of abdominal cavity by isolating specimen by performing minimally invasive surgical procedures.

The global specimen retrieval bagmarket was valued at US$ 244.7 million in 2018, and is expected to exhibit a CAGR of 4.8% over the forecast period (2019-2027).

Specimen retrieval bag market is expected to witness significant growth, owing to increasing adoption of agreement, and collaborations strategies by the market players. For instance, in March 2017, LaproSurge received 4-year framework agreement from NHS supply chain. Under the agreement LaproSurge’s minimally invasive surgery products such as scissors, instruments, retrieval bags, trocars, and 3mm instruments for laparoscopic surgery will be supplied through NHS supply chain.

 

Comments

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  

Immuno-oncology: Combination Therapies and Emerging Targets

  The study of and creation of therapies that use the immune system of the body to combat cancer are known as immuno-oncology. Our immune system, which is made up of a complex web of organs, cells, and molecules, guards us against external invaders like bacteria, fungus, and viruses that might infect us. The immune system is capable of locating and eliminating foreign objects as well as attacking aberrant cells. The immune system has the best chance of specifically destroying tumours without harming healthy tissue and having long-term memory that can stop cancer from coming back. The development of tumours can be permanently prevented or managed by a mechanism known as immunosurveillance, according to research in immuno-oncology conducted over the past 30 years. Recognition of tumour antigens is what gives the immune response its tumour specificity. The most well-established therapeutic class of IO drugs to date, immune checkpoint inhibitors have demonstrated significant effic...